National payment rate could be key to pay-for-value system

Cara Livernois | | Health Exec | Quality

The concept of value-based health care is rapidly gaining traction in the U.S., all while implementation remains a major challenge. A recent editorial in Health Affairs makes the argument that to establish true pay-for-value system, a national payment rate should be established and rooted in and adjusted for risk of the patient population, geographic variation in the cost of doing business and patient outcomes.

Read more about paying for value by following the link below:

Paying For Value: Perspective From The Front Lines

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Related Content

FDA commissioner, a veteran cardiologist, highlights ongoing issues with US healthcare system
FDA commissioner urges health systems to strengthen AI quality oversight
The top 25 children's heart hospitals in the US
Study ranks US health system dead last among wealthy nations
The 25 top US hospitals for diabetes care
The 25 best heart hospitals in the United States

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.